On July 28, 2026 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a healthcare company developing and commercializing targeted therapeutics and diagnostics for central nervous system ("CNS") cancers, reported two posters highlighting its ReSPECT-LM clinical development program and CNSide cerebrospinal fluid ("CSF") diagnostic platform will be presented at the 2026 Society for Neuro-Oncology/American Society of Clinical Oncology ("SNO/ASCO") CNS Metastases Conference, being held August 13–15, 2026, in Boston, Massachusetts.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Company and its wholly owned subsidiary, CNSide Diagnostics, LLC, will also host a sponsored symposium titled "Redefining the Management of Leptomeningeal Metastases: Integrating Diagnostics, Molecular Insights, and Emerging Therapies" on Thursday evening, August 13, 2026.
"At this year’s SNO/ASCO CNS Metastases Conference, we intend to show how Plus can help caregivers improve the detection, characterization, treatment and monitoring of patients with CNS metastases," said Marc H. Hedrick, M.D., Plus Therapeutics’ President and Chief Executive Officer. "Furthermore, we are excited to formally introduce Cerenome, Plus’ new identity, as well as new branding around our expanded focus on CNS cancer at the meeting."
Details of the poster presentations are as follows:
ReSPECT-LM Poster Presentation
Title: ReSPECT-LM: Pharmacokinetic and Pharmacodynamic Assessment of Rhenium Obisbemeda in Leptomeningeal Metastases with Emerging Data from Repeated Dosing (ReSPECT-LMM)
Presenter: Andrew Brenner, MD, PhD, University of Texas Health Science Center at San Antonio
Date and Time: Thursday, August 13, 2026, 7:15-9:00 PM ET
Location: America Ballroom at the Westin Copley Place
CNSide Poster Presentation
Title: Economic impact of earlier detection and therapeutic management of leptomeningeal metastases using CNSide: a cost-of-care analysis
Presenter: Kelly Kreitzburg Ondrasek, PhD, Medical Science Liaison at CNSide Diagnostics
Date and Time: Thursday, August 13, 2026, 7:15-9:00 PM ET
Location: America Ballroom at the Westin Copley Place
Sponsored Symposium
Title: Redefining the Management of Leptomeningeal Metastases: Integrating Diagnostics, Molecular Insights, and Emerging Therapies
Date and Time: Thursday, August 13, 2026, from 6:15 PM to 7:15 PM ET
The symposium will bring together leading key opinion leaders to discuss the evolving management of leptomeningeal metastases, including:
The current treatment landscape, unmet needs and clinical challenges
The expanding role of CSF-based biomarkers in precision diagnostics
Emerging therapeutic strategies and future directions for treatment
The role of data analytics, AI and precision medicine in patient management
What precision care could look like in 2030
The symposium is presented by Plus Therapeutics and CNSide Diagnostics. Additional symposium information and a form to request a recording of the presentation are available here.
Following the presentation at the conference, the posters will be available on the Publications page of the Company’s website.
About REYOBIQ (Rhenium-186 Obisbemeda)
REYOBIQ, or rhenium-186 obisbemeda, is a novel injectable radiotherapy specifically formulated to deliver direct, targeted, high-dose radiation to CNS tumors while potentially limiting radiation exposure to healthy tissue. REYOBIQ is being evaluated for the treatment of recurrent glioblastoma, leptomeningeal metastases and pediatric brain cancer through the ReSPECT clinical development program.
(Press release, Plus Therapeutics, JUL 28, 2026, View Source [SID1234669463])